NCT04349267View on ClinicalTrials.gov

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 14, 2020

Primary Completion Date

August 22, 2024

Study Completion Date

August 22, 2024

Conditions
Advanced Solid Tumor
Interventions
BIOLOGICAL

BMS-986315

Specified dose on specified days

BIOLOGICAL

nivolumab

Specified dose on specified days

BIOLOGICAL

cetuximab

Specified dose on specified days

Trial Locations (8)

38138

Local Institution - 0001, Germantown

57104

Local Institution - 0028, Sioux Falls

T6X 1E8

Local Institution - 0014, Edmonton

V5Z 4E6

Local Institution - 0011, Vancouver

M5G 2M9

Local Institution - 0004, Toronto

H2X 3E4

Local Institution - 0005, Montreal

K1H 8L6

Local Institution - 0013, Ottawa

06100

Local Institution, Mexico City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04349267 - Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter